866-997-4948(US-Canada Toll Free)

Metastatic Melanoma - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Sep 2013

Category :

Oncology

No. of Pages : 347 Pages


Global Markets Directs, \'Metastatic Melanoma - Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Melanoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Melanoma. Metastatic Melanoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Melanoma.
  • A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Melanoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Metastatic Melanoma Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Metastatic Melanoma 12
Metastatic Melanoma Therapeutics under Development by Companies 14
Metastatic Melanoma Therapeutics under Investigation by Universities/Institutes 19
Late Stage Products 21
Comparative Analysis 21
Mid Clinical Stage Products 22
Comparative Analysis 22
Early Clinical Stage Products 23
Comparative Analysis 23
Discovery and Pre-Clinical Stage Products 24
Comparative Analysis 24
Metastatic Melanoma Therapeutics - Products under Development by Companies 25
Metastatic Melanoma Therapeutics - Products under Investigation by Universities/Institutes 30
Companies Involved in Metastatic Melanoma Therapeutics Development 31
Bristol-Myers Squibb Company 31
F. Hoffmann-La Roche Ltd. 32
Vical Incorporated 33
Amgen Inc. 34
Sanofi-Aventis 35
Eli Lilly and Company 36
GlaxoSmithKline plc 37
Genentech, Inc. 38
Delcath Systems, Inc. 39
Piramal Healthcare Limited 40
Millennium Pharmaceuticals, Inc. 41
Novartis AG 42
Eisai Co., Ltd. 43
Ono Pharmaceutical Co., Ltd. 44
Pfizer Inc. 45
Celgene Corporation 46
Bayer AG 47
Incyte Corporation 48
Luitpold Pharmaceuticals, Inc. 49
Merck KGaA 50
Momenta Pharmaceuticals, Inc. 51
Marshall Edwards, Inc. 52
AVAX Technologies, Inc. 53
Oncolytics Biotech Inc. 54
Osta Biotechnologies Inc. 55
Antisoma plc 56
Progen Pharmaceuticals Limited 57
Provectus Pharmaceuticals, Inc. 58
BioAlliance Pharma SA 59
Morphotek, Inc. 60
CIMAB S.A. 61
DNA Therapeutics S.A. 62
Philogen S.p.A. 63
siRNAsense AS 64
Curacyte AG 65
Altor BioScience Corporation 66
Deciphera Pharmaceuticals, LLC 67
Affichem 68
Immutep S.A. 69
Omeros Corporation 70
AB Science 71
CureTech Ltd. 72
WntResearch AB 73
Archer Biosciences, Inc 74
Life Science Pharmaceuticals, Incorporated 75
Cancer Therapeutics CRC Pty Ltd 76
Targa Therapeutics Corp. 77
Cytavis Biopharma GmbH 78
n.v. BRUCELLS s.a. 79
California Stem Cell, Inc. 80
Gradalis Inc. 81
Lipotek Pty Ltd 82
Metastatic Melanoma - Therapeutics Assessment 83
Assessment by Monotherapy Products 83
Assessment by Combination Products 84
Assessment by Route of Administration 85
Assessment by Molecule Type 88
Drug Profiles 91
pasireotide - Drug Profile 91
nilotinib - Drug Profile 94
sagopilone - Drug Profile 97
axitinib - Drug Profile 99
sunitinib malate - Drug Profile 102
Darleukin - Drug Profile 106
denenicokin - Drug Profile 108
verubulin - Drug Profile 110
trametinib dimethyl sulfoxide - Drug Profile 113
ALS-357 - Drug Profile 116
velimogene aliplasmid - Drug Profile 117
velimogene aliplasmid - Drug Profile 119
cobimetinib - Drug Profile 121
M-402 - Drug Profile 122
vemurafenib - Drug Profile 123
vemurafenib - Drug Profile 126
vemurafenib - Drug Profile 128
paclitaxel albumin-bound - Drug Profile 131
pimasertib - Drug Profile 133
ramucirumab - Drug Profile 136
talimogene laherparepvec - Drug Profile 140
M-Vax - Drug Profile 142
muparfostat - Drug Profile 144
pelareorep - Drug Profile 146
PV-10 - Drug Profile 150
triphendiol - Drug Profile 152
elacytarabine - Drug Profile 154
MORAb-004 - Drug Profile 156
pidilizumab - Drug Profile 158
AS-1409 - Drug Profile 160
Hemoximer - Drug Profile 162
aviscumine - Drug Profile 164
ecromeximab - Drug Profile 165
veliparib - Drug Profile 167
BreMel/TNF-a - Drug Profile 169
arsenic trioxide + disulfiram - Drug Profile 170
LOC-paclitaxel - Drug Profile 171
Alpha-Gal Glycosphingolipids - Drug Profile 172
Autologous Dendritic Cell-Adenovirus CCL21 Vaccine - Drug Profile 173
melphalan - Drug Profile 174
AF-122 - Drug Profile 176
Box-5 - Drug Profile 177
TAK-733 - Drug Profile 178
Lipovaxin-MM - Drug Profile 180
GSK-2132231A - Drug Profile 181
masitinib - Drug Profile 183
astuprotimut-R - Drug Profile 185
rebastinib - Drug Profile 186
nivolumab - Drug Profile 188
VCL-IM01 - Drug Profile 191
OB-28 - Drug Profile 192
4-Peptide Melanoma Vaccine - Drug Profile 194
talabostat - Drug Profile 195
dabrafenib + trametinib - Drug Profile 197
TriMix-DC Vaccine - Drug Profile 199
dabrafenib - Drug Profile 200
MART-1 Dendritic Cell Vaccine + gp100 Dendritic Cell Vaccine + Tyrosinase Dendritic Cell Vaccine + [aldesleukin] - Drug Profile 202
INCB-24360 - Drug Profile 203
Anti-NY ESO-1 TCR-Gene Engineered Autologous Lymphocytes + [aldesleukin] + [cyclophosphamide] + [fludarabine phosphate] - Drug Profile 205
F5 TCR transgenic cells + MART-1 peptide pulsed dendritic cells + [cyclophosphamide] + [fludarabine] - Drug Profile 206
ESO-1 Peptide Vaccine - Drug Profile 207
Dendritic Cells Vaccine - Drug Profile 208
VLP Vaccine + [cyclophosphamide] + [fludarabine phosphate] - Drug Profile 209
Anti-P53 T-Cell Receptor-Transduced Peripheral Blood Lymphocytes + Dendritic Cell Vaccine + [aldesleukin] - Drug Profile 210
Anti-Mart-1 TCR-Gene Engineered Lymphocytes - Drug Profile 211
Anti-Mart-1/Anti-gp100 TCR-Gene Engineered Lymphocytes - Drug Profile 212
GSK-2241658A - Drug Profile 214
Anti-gp 100:154 TCR PBL Peptide Vaccine - Drug Profile 215
DPK-M3 - Drug Profile 216
DPK-M1 - Drug Profile 217
(cobimetinib + vemurafenib) - Drug Profile 218
Dendritic Cell Vaccine - Drug Profile 220
DNA IL-12 - Drug Profile 221
scFvMel/rGel - Drug Profile 223
inCVAX - Drug Profile 224
MLN-2480 - Drug Profile 226
BO-110 - Drug Profile 227
RG-7446 - Drug Profile 228
GPR19 Antagonist - Drug Profile 229
Pbi-shRNA STMN1 LP - Drug Profile 230
Contego - Drug Profile 231
Contego - Drug Profile 232
RG-7636 - Drug Profile 233
Drug Targeting FAK, FLT3 And VEGFR3 - Drug Profile 234
MORAb-050 - Drug Profile 236
Dendritic Cell Vaccine + [interferon alfa-2b] - Drug Profile 237
SAR-260301 - Drug Profile 238
miRNA-7-5p - Drug Profile 239
DT-01 - Drug Profile 240
interleukin-15 - Drug Profile 242
Recombinant IGFBP7 - Drug Profile 244
Endothelin Receptor Antagonist - Drug Profile 245
Tissue Factor Project - Drug Profile 246
NY-ESO-1 Targeted T cells - Drug Profile 247
Tumor Stem Cell Specific Dendritic Cell Therapy - Drug Profile 248
Saturated Lysophosphatidylcholine - Drug Profile 250
austrasulfone - Drug Profile 251
ZSG-101 - Drug Profile 252
ZSG-102 - Drug Profile 253
SVX-1 Vaccine - Drug Profile 254
Cancer Stem Cell Therapy - Drug Profile 255
IL-2 Mutein - Drug Profile 256
RG-7446 + vemurafenib - Drug Profile 257
Metastatic Melanoma Therapeutics - Drug Profile Updates 258
Metastatic Melanoma Therapeutics - Discontinued Products 327
Metastatic Melanoma Therapeutics - Dormant Products 328
Metastatic Melanoma - Product Development Milestones 332
Featured News & Press Releases 332

Appendix 339
Methodology 339
Coverage 339
Secondary Research 339
Primary Research 339
Expert Panel Validation 339
Contact Us 340
Disclaimer 340

List of Table


Number of Products Under Development for Metastatic Melanoma, H2 2013 19
Products under Development for Metastatic Melanoma - Comparative Analysis, H2 2013 20
Number of Products under Development by Companies, H2 2013 22
Number of Products under Development by Companies, H2 2013 (Contd..1) 23
Number of Products under Development by Companies, H2 2013 (Contd..2) 24
Number of Products under Development by Companies, H2 2013 (Contd..3) 25
Number of Products under Investigation by Universities/Institutes, H2 2013 27
Comparative Analysis by Late Stage Development, H2 2013 28
Comparative Analysis by Mid Clinical Stage Development, H2 2013 29
Comparative Analysis by Early Clinical Stage Development, H2 2013 30
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 31
Products under Development by Companies, H2 2013 32
Products under Development by Companies, H2 2013 (Contd..1) 33
Products under Development by Companies, H2 2013 (Contd..2) 34
Products under Development by Companies, H2 2013 (Contd..3) 35
Products under Development by Companies, H2 2013 (Contd..4) 36
Products under Investigation by Universities/Institutes, H2 2013 37
Bristol-Myers Squibb Company, H2 2013 38
F. Hoffmann-La Roche Ltd., H2 2013 39
Vical Incorporated, H2 2013 40
Amgen Inc., H2 2013 41
Sanofi-Aventis, H2 2013 42
Eli Lilly and Company, H2 2013 43
GlaxoSmithKline plc, H2 2013 44
Genentech, Inc., H2 2013 45
Delcath Systems, Inc., H2 2013 46
Piramal Healthcare Limited, H2 2013 47
Millennium Pharmaceuticals, Inc., H2 2013 48
Novartis AG, H2 2013 49
Eisai Co., Ltd., H2 2013 50
Ono Pharmaceutical Co., Ltd., H2 2013 51
Pfizer Inc., H2 2013 52
Celgene Corporation, H2 2013 53
Bayer AG, H2 2013 54
Incyte Corporation, H2 2013 55
Luitpold Pharmaceuticals, Inc., H2 2013 56
Merck KGaA, H2 2013 57
Momenta Pharmaceuticals, Inc., H2 2013 58
Marshall Edwards, Inc., H2 2013 59
AVAX Technologies, Inc., H2 2013 60
Oncolytics Biotech Inc., H2 2013 61
Osta Biotechnologies Inc., H2 2013 62
Antisoma plc, H2 2013 63
Progen Pharmaceuticals Limited, H2 2013 64
Provectus Pharmaceuticals, Inc., H2 2013 65
BioAlliance Pharma SA, H2 2013 66
Morphotek, Inc., H2 2013 67
CIMAB S.A., H2 2013 68
DNA Therapeutics S.A., H2 2013 69
Philogen S.p.A., H2 2013 70
siRNAsense AS, H2 2013 71
Curacyte AG, H2 2013 72
Altor BioScience Corporation, H2 2013 73
Deciphera Pharmaceuticals, LLC, H2 2013 74
Affichem, H2 2013 75
Immutep S.A., H2 2013 76
Omeros Corporation, H2 2013 77
AB Science, H2 2013 78
CureTech Ltd., H2 2013 79
WntResearch AB, H2 2013 80
Archer Biosciences, Inc, H2 2013 81
Life Science Pharmaceuticals, Incorporated, H2 2013 82
Cancer Therapeutics CRC Pty Ltd, H2 2013 83
Targa Therapeutics Corp., H2 2013 84
Cytavis Biopharma GmbH, H2 2013 85
n.v. BRUCELLS s.a., H2 2013 86
California Stem Cell, Inc., H2 2013 87
Gradalis Inc., H2 2013 88
Lipotek Pty Ltd, H2 2013 89
Assessment by Monotherapy Products, H2 2013 90
Assessment by Combination Products, H2 2013 91
Assessment by Stage and Route of Administration, H2 2013 94
Assessment by Stage and Molecule Type, H2 2013 97
Metastatic Melanoma Therapeutics - Drug Profile Updates 265
Metastatic Melanoma Therapeutics - Discontinued Products 334
Metastatic Melanoma Therapeutics - Dormant Products 335
Metastatic Melanoma Therapeutics - Dormant Products (Contd..2) 336
Metastatic Melanoma Therapeutics - Dormant Products (Contd..4) 337
Metastatic Melanoma Therapeutics - Dormant Products (Contd..6) 338

List of Chart


Number of Products under Development for Metastatic Melanoma, H2 2013 19
Products under Development for Metastatic Melanoma - Comparative Analysis, H2 2013 20
Products under Development by Companies, H2 2013 21
Products under Investigation by Universities/Institutes, H2 2013 26
Late Stage Products, H2 2013 28
Mid Clinical Stage Products, H2 2013 29
Early Clinical Stage Products, H2 2013 30
Discovery and Pre-Clinical Stage Products, H2 2013 31
Assessment by Monotherapy Products, H2 2013 90
Assessment by Combination Products, H2 2013 91
Assessment by Route of Administration, H2 2013 92
Assessment by Stage and Route of Administration, H2 2013 93
Assessment by Molecule Type, H2 2013 95
Assessment by Stage and Molecule Type, H2 2013 96

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *